Sutro Biopharma (STRO) Enterprise Value (2016 - 2025)

Sutro Biopharma has disclosed Enterprise Value across 10 years of filings, most recently posting -$141.4 million for Q4 2025.

• Enterprise Value for Q4 2025 came in at -$141.4 million, up 55.37% year-over-year; the trailing twelve-month figure through Dec 2025 was -$141.4 million (up 55.37% YoY), and the FY2025 annual result was -$141.4 million, up 55.37% from the prior year.
• Enterprise Value came in at -$141.4 million for Q4 2025 at Sutro Biopharma, up from -$167.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$91.7 million in Q2 2021 to a low of -$388.3 million in Q3 2024.
• The 5-year median for Enterprise Value is -$197.5 million (2021), against an average of -$210.6 million.
• Across the five-year window, Enterprise Value soared 63.22% in 2023 and slumped 184.96% in 2024, its largest moves.
• Sutro Biopharma's Enterprise Value stood at -$160.8 million in 2021, then slumped by 88.08% to -$302.3 million in 2022, then soared by 63.22% to -$111.2 million in 2023, then plunged by 184.96% to -$316.9 million in 2024, then soared by 55.37% to -$141.4 million in 2025.
• The last three Enterprise Value figures came in at -$141.4 million (Q4 2025), -$167.6 million (Q3 2025), and -$205.1 million (Q2 2025), per Business Quant data.